When it comes to training artificial intelligence, OpenAI and Babylon Biosciences have shown that experienced hands can help ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront to secure options on next-gen small interfering RNA (siRNA) ...

Allogene Therapeutics is cutting back to stretch its cash runway into the second half of 2027, laying off 28% of its ...

Acelyrin’s shareholders have decided to power ahead with a planned merger with immune-mediated disease specialist Alumis, ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Kyverna Therapeutics may consider it had an “exceptional start to the year,” but that didn’t immunize the cell therapy ...

GSK has already moved on from its decision to drop a cancer asset on Tuesday by snagging a late-stage liver disease candidate ...

San Diego-based RNA biotech Arcturus is doubling down on mRNA therapeutics and stepping back from earlier-stage vaccine work ...

The federal government is slashing $450 million in grant funding to Harvard University, adding on to the $2.2 billion that ...

Atara Biotherapeutics continues to salami slice its head count, this time laying off 30% of what remains of the biopharma's ...

Stylus Medicine is unsheathing, penning a mission to develop next-gen in vivo genetic medicines with $85 million in hand, ...

GSK has stopped development of anti-TIGIT antibody belrestotug. | GSK has stopped development of anti-TIGIT antibody ...